

EYSUVIS - (0.25% ; SUSPENSION/DROPS)

Generic Name	LOTEPREDNOL ETABONATE	Innovator	Alcon
Dosage	0.25% ; SUSPENSION/DROPS	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.